Dementia and its Relations Between the Late 20th and 21st Century
DOI:
https://doi.org/10.14738/assrj.107.15071Keywords:
Dementia, Alzheimer’s disease, pharmaceutical drugs, diagnostics, comorbiditiesAbstract
This study was conducted to examine changes in the beliefs and contents of articles on dementia from the 20th century. Factors analyzed included the form of dementia, pharmaceutical drugs, source country and income of the first author, diagnostics, and the year of publication. All articles (N=202) analyzed were published between January 1st, 1984, and December 31st, 2022. Inter-rater reliability was assessed and there was an 89.4 percent agreement amongst raters. All articles were analyzed through both PubMed and PsycInfo. Our results proved that a significant number of articles discussed Alzheimer’s disease. Scientific perspectives on the cause of dementia have not changed significantly between the 20th and 21st century. Additionally, there were no significant differences between high-, middle- and low-income countries discussing pharmaceutical drugs in literature.
References
Boscart, V. M., McNeill, S., & Grinspun, D. (2019). Dementia care in Canada: Nursing recommendations. Canadian Journal on Aging / La Revue Canadienne Du Vieillissement, 38(03), 407–418. https://doi.org/10.1017/s071498081800065x
BUCKS, R. S., ASHWORTH, D. L., WILCOCK, G. K., & SIEGFRIED, K. (1996). Assessment of activities of daily living in dementia: Development of the Bristol activities of Daily Living Scale. Age and Ageing, 25(2), 113–120. https://doi.org/10.1093/ageing/25.2.113
Clarnette, R. M., & Patterson, C. J. (1994). Hypothyroidism: Does treatment cure dementia? Journal of Geriatric Psychiatry and Neurology, 7(1), 23–27. https://doi.org/10.1177/089198879400700105
DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of alzheimer’s disease. Molecular Neurodegeneration, 14(1). https://doi.org/10.1186/s13024-019-0333-5
Di Feo, G. M., & O’Connell, M. (2022). Scientific perspectives on autism over time. Advances in Social Sciences Research Journal, 9(12), 161–174. https://doi.org/10.14738/assrj.912.13552
Di Feo, G., & Whissell, C. (2020). Changes in the style and contents of abstracts from the Journal of Consulting and clinical psychology between the 1960s and the 2010s. Advances in Social Sciences Research Journal, 7(10), 546–551. https://doi.org/10.14738/assrj.710.9215
Gatz, M., Mortimer, J. A., Fratiglioni, L., Johansson, B., Berg, S., Reynolds, C. A., & Pedersen, N. L. (2006). Potentially modifiable risk factors for dementia in identical twins. Alzheimer's & Dementia, 2(2), 110–117. https://doi.org/10.1016/j.jalz.2006.01.002
Grabowski, H., & Vernon, J. (2000). The determinants of Pharmaceutical Research and Development Expenditures. Journal of Evolutionary Economics, 10(1–2), 201–215. https://doi.org/10.1007/s001910050012
Lee, A. H., & Weintraub, D. (2012). Psychosis in parkinson's disease without dementia: Common and comorbid with other non-motor symptoms. Movement Disorders, 27(7), 858–863. https://doi.org/10.1002/mds.25003
Lopes, M. A., Hototian, S. R., Reis, G. C., Elkis, H., & Bottino, C. M. (2007). Systematic review of dementia prevalence - 1994 to 2000. Dementia & Neuropsychologia, 1(3), 230–240. htts://doi.org/10.1590/s1980-57642008dn10300003
Pistollato, F., Ohayon, E. L., Lam, A., Langley, G. R., Novak, T. J., Pamies, D., Perry, G., Trushina, E., Williams, R. S. B., Roher, A. E., Hartung, T., Harnad, S., Barnard, N., Morris, M. C., Lai, M.-C., Merkley, R., & Chandrasekera, P. C. (2016). Alzheimer disease research in the 21st Century: Past and current failures, new perspectives, and funding priorities. Oncotarget, 7(26), 38999–39016. https://doi.org/10.18632/oncotarget.9175
Poblador-Plou, B., Calderón-Larrañaga, A., Marta-Moreno, J., Hancco-Saavedra, J., Sicras-Mainar, A., Soljak, M., & Prados-Torres, A. (2014). Comorbidity of dementia: A cross-sectional study of primary care older patients. BMC Psychiatry, 14(1). https://doi.org/10.1186/1471-244x-14-84
Portnow, L. H., Vaillancourt, D. E., & Okun, M. S. (2013). The history of Cerebral Pet Scanning: From physiology to cutting-edge technology. Neurology, 80(10), 952–956. https://doi.org/10.1212/wnl.0b013e318285c135
Prince M, Acosta D, Chiu H, Scazufca M, Varghese M (2003) Dementia diagnosis in developing countries: a crosscultural validation study. The Lancet 361: 909–917.
Pickett, J., & Brayne, C. (2019). The scale and profile of Global Dementia Research Funding. The Lancet, 394(10212), 1888–1889. https://doi.org/10.1016/s0140-6736(19)32599-1 140
Hampel, H., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., Chiesa, P. A., Colliot, O., Coman, C.-M., Dubois, B., Duggento, A., Durrleman, S., Ferretti, M.-T., George, N., Genthon, R., Habert, M.-O., … Lista, S. (2018). Revolution of alzheimer precision neurology. Passageway of Systems Biology and neurophysiology1. Journal of Alzheimer's Disease, 64(s1). https://doi.org/10.3233/jad-179932
Smith-Bindman, R., Kwan, M. L., Marlow, E. C., Theis, M. K., Bolch, W., Cheng, S. Y., Bowles, E. J., Duncan, J. R., Greenlee, R. T., Kushi, L. H., Pole, J. D., Rahm, A. K., Stout, N. K., Weinmann, S., & Miglioretti, D. L. (2019). Trends in use of medical imaging in US Health Care Systems and in Ontario, Canada, 2000-2016. JAMA, 322(9), 843. https://doi.org/10.1001/jama.2019.11456
Solomon, A., Dobranici, L., Kåreholt, I., Tudose, C., & Lăzărescu, M. (2011). Comorbidity and the rate of cognitive decline in patients with alzheimer dementia. International Journal of Geriatric Psychiatry, 26(12), 1244–1251. https://doi.org/10.1002/gps.2670
Schultz-Larsen, K., Lomholt, R. K., & Kreiner, S. (2007). Mini-mental status examination: A short form of MMSE was as accurate as the original MMSE in predicting dementia. Journal of Clinical Epidemiology, 60(3), 260–267. https://doi.org/10.1016/j.jclinepi.2006.06.008
Swanson, K. A., & Carnahan, R. M. (2007). Dementia and Comorbidities: An overview of diagnosis and management. Journal of Pharmacy Practice, 20(4), 296–317. https://doi.org/10.1177/0897190007308594
Sobczak, S., Olff, M., Rutten, B., Verhey, F., & Deckers, K. (2021). Comorbidity rates of posttraumatic stress disorder in dementia: A systematic literature review. European Journal of Psychotraumatology, 12(1). https://doi.org/10.1080/20008198.2021.1883923
Tanaka, M., Török, N., & Vécsei, L. (2022). Novel pharmaceutical approaches in dementia. NeuroPsychopharmacotherapy, 2803–2820. https://doi.org/10.1007/978-3-030-62059-2_444
Tanzi, M. G. (2019). Anticholinergic drug exposure increases risk of dementia. Pharmacy Today, 25(9), 4. https://doi.org/10.1016/j.ptdy.2019.08.028
Kaitin, K. I., & DiMasi, J. A. (2010). Pharmaceutical innovation in the 21st Century: New drug approvals in the first decade, 2000–2009. Clinical Pharmacology & Therapeutics, 89(2), 183–188. https://doi.org/10.1038/clpt.2010.286
Karantzoulis, S., & Galvin, J. E. (2011). Distinguishing alzheimer’s disease from other major forms of dementia. Expert Review of Neurotherapeutics, 11(11), 1579–1591. https://doi.org/10.1586/ern.11.155
Kindermann, S. S., Dolder, C. R., Bailey, A., Katz, I. R., & Jeste, D. V. (2002). Pharmacological treatment of psychosis and agitation in elderly patients with dementia. Drugs & Aging, 19(4), 257–276. https://doi.org/10.2165/00002512-200219040-00002
Koyama, A., Steinman, M., Ensrud, K., Hillier, T. A., & Yaffe, K. (2013). Ten-year trajectory of potentially inappropriate medications in very old women: Importance of cognitive status. Journal of the American Geriatrics Society, 61(2), 258–263. https://doi.org/10.1111/jgs.12093
Zagórska, A., Czopek, A., Fryc, M., Jaromin, A., & Boyd, B. J. (2023). Drug Discovery and Development targeting dementia. Pharmaceuticals, 16(2), 151. https://doi.org/10.3390/ph16020151
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gian Marco Di Feo, Michael Emond, Kassra Ghassemkhani
This work is licensed under a Creative Commons Attribution 4.0 International License.
